“Having that vertical integration of raw materials and mRNA manufacturing all set up within a Syngene site is where the firm believes it is “better prepared” to serve clients with advanced therapies, which are more biologics-based.”
Syngene is seeing significant interest from clients in oligonucleotide-based therapeutics and maintained that the firm “stands out” since it has a cGMP oligonucleotide manufacturing facility, “because of which we can provide oligos of this nature that can go into clinical trials.
It deploys advanced technology platforms to provide a comprehensive set of oligonucleotide synthesis services, ranging from development to the manufacture of chemically synthesized oligonucleotides.
Syngene’s capabilities also include gene editing platforms that support multiple modalities, including CAR-T research. While it is not into the manufacturing part yet, Bhalgat sees that as a “natural progression” of the firm’s collaboration with clients who are in discovery.
“Once clients progress their molecules from discovery to development to manufacturing, that’s where we will be ready with what the needs of the clients are at the time”
“We’ve not just been a pure-play manufacturer, but we’ve been a manufacturer that is well versed in handling microbial, mammalian, yeast and other expression systems. So therefore, our range of knowledge, diversity, experience positions us more as a preferred player”
Moreover, biologics supporting services, he explained, are more complicated given the need for a lot more analytical/ process characterization and a “lot more work in terms of putting a dossier together.”
Syngene is set up to do all of that in-house and also boasts the only facility in India which is a GLP-certified laboratory to do work such as viral clearance tests. These aspects, he said, make the firm “more of a one-stop shop,” along with the knowledge base that it brings.
“A key advantage for Syngene is because we’re able to offer drug discovery, all the way to manufacturing and everything that is needed in between and specifically for biologics. These are things that make us clearly head and shoulders above our competition.
For us, we look at biologics as a key driver of growth.”
Loading suggestions...